Facebook
Twitter
LinkedIn
Forward
Managing the Physical, Neuropsychiatric, and Cognitive Health Needs of Patients With Duchenne Muscular Dystrophy
Overview
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
Learning Objectives
After completing this educational activity, participants should be better able to:
- Provide DMD treatment in concordance with guidelines and patient-centered care strategies
- Avoid delayed detection and intervention for behavioral-psychosocial comorbidities of DMD
Target Audience
Psychiatrists (pediatric and adult), child psychologists, neurologists, neurologists (pediatric and adult), psychiatry and neurology NPs and PAs, and other clinicians who treat patients with DMD.
Abstract
Join Dr. Natalie Truba from Nationwide Children’s Hospital in Columbus, OH for a two-part, documentary-style video centered on managing the behavioral needs of patients with Duchenne muscular dystrophy (DMD). Through this activity, participants can enhance their awareness of common psychosocial comorbidities that manifest in DMD, such as attention-deficit hyperactivity disorder, oppositional defiant disorder, and obsessive-compulsive disorder. Additionally covered in this video are antecedent management strategies for patients with DMD and a review of the pharmacotherapies that should be used to manage common neuropsychiatric comorbidities. By intervening in a timely manner, clinicians can limit morbidity associated with DMD and minimize disruption to caregivers. To provide a more complete, engaging learning experience for learners, the video integrates segments featuring insights from actual patients with DMD and their family member caregivers.
Support Statement
This initiative is supported by an educational grant from PTC Therapeutics, Inc.
Learning Objectives
After completing this educational activity, participants should be better able to:
- Provide DMD treatment in concordance with guidelines and patient-centered care strategies
- Avoid delayed detection and intervention for behavioral-psychosocial comorbidities of DMD
Release, Review, and Expiration Dates
This CME activity was published in August 2022 and is eligible for AMA PRA Category 1 Credit™ through August 31, 2023.
Statement of Need and Purpose
Clinicians’ application of recommended standards of care in Duchenne muscular dystrophy (DMD) often vary widely across different practices. After treatment initiation, those entrusted with the care of patients with DMD sometimes underappreciate neurodevelopmental symptoms and issues relating to cognition, despite their impact on quality of life. Delayed detection and interventions for patients with comorbid attention-deficit hyperactivity disorder, autism, and obsessive-compulsive disorder lead to avoidable, suboptimal outcomes. Through targeted educational initiatives, neurologists and supporting clinicians can cultivate the skills necessary to apply recommendations from clinical guidelines, integrate new therapies into routine practice, and elevate patient satisfaction with care. Although DMD is traditionally conceived as a neuromuscular disorder, timely management of accompanying cognitive challenges is integral in efforts to improve patients’ quality of life as they transition from childhood, through adolescence, and into young adulthood.
Unlabeled and Investigational Usage
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Review Process
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter
© Copyright 2022 Physicians Postgraduate Press, Inc.
Faculty Affiliation
Natalie P. Truba, PhD
Nationwide Children’s Hospital
Columbus, OH
Financial Disclosure
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Individual Financial Disclosures
Dr. Natalie Truba has received honoraria for speaking and teaching from PTC therapeutics and the Muscular Dystrophy Association within the last 24 months, along with reimbursements for travel expenses by Parent Project Muscular Dystrophy
Accredited Provider Disclosure
Michael R. Page, PharmD, RPh
Independent Medical Director/Medical Writer
Plainsboro, New Jersey
Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.
Virginia Kimonis, MD
Peer Reviewer
Irvine, CA
Dr. Kimonis has received grant/research support from Sanofi; and has served on the advisory board for Sanofi.
None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation